Dyne Therapeutics Inc $DYN

Recent News (4)

• Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NMSG Scientific Meeting GlobeNewswire · 03 Sep 2026 - Data support the ongoing development of four investigational therapies for DMD amenable to skipping of exons 53, 45, 44 or 55, all of which are advancing into IND-enabling studies -
• Dyne Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire · 02 Sep 2026 WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically dri…
• Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights GlobeNewswire · 29 Jul 2026 - Biologics License Application (BLA) for z-rostudirsen in exon 51 DMD accepted for review by FDA; Priority Review granted; PDUFA target action date set for January 21, 2027 -
• Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD) GlobeNewswire · 20 Jul 2026 - Priority Review granted; PDUFA target action date set for January 21, 2027 -